Archives
- 2018-07
- 2019-04
- 2019-05
- 2019-06
- 2019-07
- 2019-08
- 2019-09
- 2019-10
- 2019-11
- 2019-12
- 2020-01
- 2020-02
- 2020-03
- 2020-04
- 2020-05
- 2020-06
- 2020-07
- 2020-08
- 2020-09
- 2020-10
- 2020-11
- 2020-12
- 2021-01
- 2021-02
- 2021-03
- 2021-04
- 2021-05
- 2021-06
- 2021-07
- 2021-08
- 2021-09
- 2021-10
- 2021-11
- 2021-12
- 2022-01
- 2022-02
- 2022-03
- 2022-04
- 2022-05
- 2022-06
- 2022-07
- 2022-08
- 2022-09
- 2022-10
- 2022-11
- 2022-12
- 2023-01
- 2023-02
- 2023-03
- 2023-04
- 2023-05
- 2023-06
- 2023-07
- 2023-08
- 2023-09
- 2023-10
- 2023-11
- 2023-12
- 2024-01
- 2024-02
- 2024-03
- 2024-04
- 2024-05
- 2024-06
- 2024-07
- 2024-08
- 2024-09
- 2024-10
- 2024-11
- 2024-12
- 2025-01
-
br Materials and Methods br Author
2024-04-17
Materials and Methods Author Contributions Conflicts of Interest Acknowledgments We thank Francine Jodelka for technical assistance and Gopal Thinakaran for the CTM-1 antibody. This work was financially supported by RFUMS internal research funding and NIHS10 OD 010662. Introduction A
-
pge2 Linagliptin is a recently approved dipeptidyl peptidase
2024-04-17
Linagliptin is a recently approved dipeptidyl peptidase-4 (DPP-4) inhibitor and widely considered as first-line treatment for patients with type 2 diabetes. DPP-4 is responsible for the inactivation of incretin hormones, such as glucagon-like peptide 1 (GLP-1). GLP-1 is released by the intestine aft
-
Among all the compounds the novel L derivative
2024-04-17
Among all the compounds, the novel L-748,337 derivative (23d) showed the potent human β3-AR antagonist activity and high lipolysis inhibitory activity in vitro. The LED209 sale 23d displayed 23-fold more potent β3-AR antagonist activity (EC50 = 0.5117 nM) than that of L-748,337 (EC50 = 11.91 nM) an
-
br There are three types of HT receptors
2024-04-17
There are three types of 5-HT2 receptors. 5-HT2A, 5-HT2B and 5-HT2C receptors Exhibit 46–50% overall sequence identity and couple preferentially to Gq/11 to increase inositol phosphates and cytosolic [Ca2+] and in agreement with their long known role in muscle contraction and stimulation in the br
-
jak stat inhibitor Application of the broad acting HTR antag
2024-04-16
Application of the broad-acting 5-HTR antagonist methiothepin (Bard et al., 1996, Hoyer et al., 1994, Peroutka, 1990) converted the TBS-induced response of both thalamocortical and intracortical A1 synapses from LTP to LTD, an effect that was mimicked by the selective 5-HT2R antagonist ketanserin (L
-
The obtained results indicate that even when the impairment
2024-04-16
The obtained results indicate that even when the impairment of the same forms of memory are present, amnesia can develop in different ways. Impairment of memory reconsolidation in the conditioned food aversion model through both the serotonin receptor antagonist and the antagonist of NMDA glutamate
-
br Acknowledgments br Introduction Cancer
2024-04-16
Acknowledgments Introduction Cancer is the leading cause of mortality in the United States for those between the ages of 40–79 years, surpassing heart diseases by more than 100,000 deaths [1]. The cause of most cancer subtypes remains idiopathic and may arise out of ‘bad luck’ among otherwise
-
What can we learn about the anticancer therapeutic
2024-04-16
What can we learn about the anticancer therapeutic efficacy of Aurora kinase inhibitors from our experience with the Bcr-Abl inhibitors and the long term clinical consequence of their use in treating leukemias? As discussed, all Aurora kinase inhibitors developed to date are ATP-competitive inhibito
-
br Conflicts of interest br Introduction Phosphatidic
2024-04-16
Conflicts of interest Introduction Phosphatidic Doxorubicin HCl phosphatase (PAP) enzymes are responsible for catalyzing the reaction that dephosphorylates phosphatidic acid (PA), which in turn produces diacylglycerol (DAG) and a phosphate group during phospholipid regulation (Fig. 1A) [1]. S
-
Upregulation of ACLY is common
2024-04-16
Upregulation of ACLY is common in many cancers (Kuhajda, 2000, Milgraum et al., 1997, Swinnen et al., 2004, Yahagi et al., 2005). This is in part due to the transcriptional activation by SREBP-1 resulting from the activation of the PI3K/AKT pathway in cancers (Kim et al., 2010, Nadler et al., 2001,
-
Transient transfection with ATR kinase dead
2024-04-16
Transient transfection with ATR kinase-dead (D2475→A) [30] and ATM kinase-dead (D2870→Ala and N2875→K) [31] constructs was performed using Fugene 6 (Roche Applied Science, Indianapolis). Three microliters of fugene 6+1μg plasmid was used in transfections using 6-well plates at 2×105 cells/well and a
-
The growth of cancer can
2024-04-16
The growth of cancer can control by inhibiting the rate of cell proliferation or increasing the rate of selective apoptosis and effectiveness of anticancer agents varies according to genetic constitution of cancer. Hence, we investigated the anticancer activity of arginase against different kinds of
-
L-NMMA citrate As a neuropeptide Apelin also
2024-04-16
As a neuropeptide, Apelin also has a critical role in cardiovascular diseases. Systemic administration of Apelin exert vasodilatory and antihypertensive effects [33]. Meanwhile, the apelin-APJ signal transduction pathway is related to age-associated cardiovascular diseases [34]. It has been known th
-
AP plays a pivotal role in
2024-04-16
AP-1 plays a pivotal role in transcriptional regulation of MMP expression. The decoy technique allows the neutralization of AP-1 without any transfection reagents for cellular uptake that cause potential side effects or immune reactions. This energy-dependent transport mechanism of “naked” dODN is c
-
We made a number of
2024-04-16
We made a number of choices in the original design of our experiments. First, we used only portions of the 5′ and 3′ regulatory elements from S. cerevisiae. The sequences of these regions were known [32] and our goal was to express the Pf-DHFR at low levels. In fact, our choice of only 600 bp of the
15361 records 137/1025 page Previous Next First page 上5页 136137138139140 下5页 Last page